文献速递姑息放疗与转移瘤放疗物理与技术

非脊柱骨转移的立体定向体部放疗:基于病例的放射外科协会综述

Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: A Case-Based Radiosurgery Society Review.
PubMed 文献 · Pract Radiat Oncol · 2026-04-19

该综述通过肋骨、颅底和股骨三个非脊柱骨转移(NSBM)病例,结合文献回顾与专家共识,提出SBRT在NSBM中的适用条件、靶区勾画、剂量约束及计划要点。SBRT可考虑用于寡转移、预后良好且追求持久局部控制或症状缓解的患者,也可用于放射抵抗组织学或需更好保护危及器官者。

要点

  • SBRT可考虑用于寡转移、预后良好、目标为持久局部控制或症状缓解的NSBM患者。
  • 应融合可用MRI或PET/CT以改善靶区勾画,临床靶区(CTV)外放一般考虑5 mm以覆盖微病灶。
  • 计划靶区(PTV)外放应保持≤3 mm;CTV邻近危及器官时可优选分次SBRT以满足剂量约束。

核心结论

  • SBRT可考虑用于寡转移、预后良好、目标为持久局部控制或症状缓解的NSBM患者,也可用于放射抵抗组织学或改善危及器官保护。
  • 放射外科协会的病例综述结合专家讨论与共识推荐,为NSBM中SBRT的合理使用提供指导。

研究设计与样本

  • 放射外科协会病例综述,选择肋骨、颅底和股骨三个NSBM病例进行讨论,并回顾相关文献及未来研究方向。

主要发现

  • 在合适的患者选择、靶区勾画、处方剂量、危及器官剂量约束和治疗计划下,SBRT可有效用于NSBM。
  • 应融合可用MRI或PET/CT以改善靶区勾画;临床靶区外放一般考虑5 mm以覆盖微病灶。
  • 计划靶区外放应保持≤3 mm;CTV邻近危及器官时可优选分次SBRT以满足剂量约束。
  • 负重、溶骨性或MIRELS评分高的长骨NSBM应由骨科医生评估。

关键数值与推荐

  • 临床靶区(CTV)外放一般考虑5 mm以覆盖微观病灶。
  • 计划靶区(PTV)外放应保持小于或等于3 mm。
  • SBRT可单次给予,但CTV邻近危及器官时可优选分次SBRT以满足剂量约束。
  • 负重、溶骨性或MIRELS评分高的长骨NSBM应由骨科医生评估。

临床怎么用

  • 对寡转移、预后良好的NSBM患者,可以持久局部控制或症状缓解为目标考虑SBRT。
  • 放射抵抗组织学或需改善危及器官保护时,可考虑SBRT。
  • 计划前应融合可用MRI或PET/CT,CTV一般外放5 mm,PTV外放≤3 mm。
  • CTV邻近危及器官时,优选分次SBRT以满足剂量约束。
  • 负重、溶骨性或MIRELS评分高的长骨NSBM应请骨科医生评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Growing evidence supports stereotactic body radiation therapy (SBRT) over conventional radiation therapy for spine bone metastases, with an expanding role in nonspine bone metastases (NSBM). Our case-based review aims to inform radiation oncologists in the appropriate use of SBRT for representative cases of NSBM. METHODS AND MATERIALS: Three cases were selected for discussion: (1) rib, (2) skull base, and (3) femur. Relevant literature was reviewed, and areas for future investigation were discussed. RESULTS: SBRT can be effectively delivered in NSBM with appropriate patient selection, target volume delineation, prescription dose, organs at risk (OARs) dose constraints, and treatment planning. CONCLUSIONS: The Radiosurgery Society's case-based review offers guidance on the appropriate use of SBRT in NSBM with discussions and consensus recommendations from experts. SBRT can be considered for patients with oligometastatic disease with a favorable prognosis in whom the goal is durable local control and/or symptom relief. It can be considered for radioresistant histologies and improved OAR sparing. Available magnetic resonance imaging or positron emission tomography/computed tomography should be fused to improve target volume delineation. A clinical target volume margin, generally of 5 mm, should be considered to cover microscopic disease. As bones are easily visualized on daily images acquired for accurate and precise setup of patients, a planning target volume margin should be kept less than or equal to 3 mm. Although SBRT can be delivered in 1 fraction, fractionated SBRT may be preferred to meet dose constraints when the clinical target volume is adjacent to the OARs. NSBM of long bones that are weight bearing, lytic, or have a high MIRELS score should be evaluated by an orthopedic surgeon.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu Y, Goldrich N, Redmond KJ, et al. Stereotactic Body Radiation Therapy for Nonspine Bone Metastases: A Case-Based Radiosurgery Society Review. Pract Radiat Oncol. 2026. PMID: 42009282. doi:10.1016/j.prro.2026.04.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。